• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG COBAS® LIAT® SARS-COV-2 & INFLUENZA A/B; COVID-19 MULTI-ANALYTE RESPIRATORY PANEL NUCLEIC ACID DEVICES

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG COBAS® LIAT® SARS-COV-2 & INFLUENZA A/B; COVID-19 MULTI-ANALYTE RESPIRATORY PANEL NUCLEIC ACID DEVICES Back to Search Results
Catalog Number 09211101190
Device Problems Incorrect, Inadequate or Imprecise Result or Readings (1535); Unexpected Therapeutic Results (1631); Output Problem (3005); Non Reproducible Results (4029)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 01/09/2022
Event Type  malfunction  
Event Description
In light of the covid-19 pandemic and the subsequent emergency use authorizations (euas) for sars-cov-2 diagnostic tests, the agency has requested heightened reporting beyond the reasonably suggests requirements of 803 to include allegations of false positive or false negative results independent of harm or malfunction or off-label use.Pursuant to the agency¿s instruction, we hereby submit this mdr.A customer from the us alleged discrepant results for two patients' samples when using the cobas® sars-cov-2 & influenza a/b nucleic acid test on the cobas® liat® system.The customer reported that on (b)(6) 2022, the initial sample for patient 1 tested with cobas liat generated influenza b positive, sars-cov-2 negative and influenza a negative results.The same sample was repeat tested on the same cobas liat analyzer and on a different platform (genexpert).Both retests generated negative results across all targets.The negative results were reported.On (b)(6) 2022, the initial sample for patient 2 tested with cobas liat generated negative results for sars-cov-2, influenza a&b.Per lab policy, due to the patient exhibiting respiratory symptoms, the patient was retested on a different cobas liat analyzer and on a different platform (genexpert).Both generated a sars-cov-2 positive result, and the positive results were reported.A viral respiratory panel was ordered, with results unknown.The customer collected nasopharyngeal samples using the bd vtm 3ml.No apparent harm or injury occurred in relation to the event.An investigation was conducted to evaluate the customer¿s allegation.Per fda guidance on eua, two (2) mdrs will be filed.
 
Manufacturer Narrative
Throughout the data analysis, a systematic issue was not observed and a product problem was not found.Review of the data showed normal pcr curves, without any abnormalities typically associated with erroneous results.The discrepancy for both patients show a weak amplification and late ct values, which could be explained by a low titer sample.Samples near or below the limit of detection (lod) of the test may generate wavering results on repeat testing.Viral material near the lod can be caused either from low titer samples or a low level of laboratory contamination.In addition, the lod and the type of influenza and sars-cov-2 viral strains detected differs significantly between the cobas® sars-cov-2 & influenza a/b assay on the cobas® liat® system and the cepheid genexpert assays.As such, results with one assay may not be reproducible with a different assay.An investigation was performed on the reagent lots used and ruled out any contribution.The most likely cause for the discrepancy observed is due to the sample having a low viral load where results are known to waiver and the differences in testing methods.(b)(4).
 
Manufacturer Narrative
Replaced incorrect code unexpected therapeutic results (a0909) with output problem (a09).(b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
COBAS® LIAT® SARS-COV-2 & INFLUENZA A/B
Type of Device
COVID-19 MULTI-ANALYTE RESPIRATORY PANEL NUCLEIC ACID DEVICES
Manufacturer (Section D)
ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG
1080 us highway 202 south
branchburg NJ 08876
Manufacturer (Section G)
ROCHE MOLECULAR SYSTEMS, INC. - BRANCHBURG
1080 us highway 202 south
na
branchburg NJ 08876
Manufacturer Contact
stacie-ann creighton
1080 us hwy 202 s
na
branchburg, NJ 08876
9082537112
MDR Report Key13366095
MDR Text Key295611297
Report Number2243471-2022-00142
Device Sequence Number1
Product Code QLT
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
EUA201779
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Health Professional
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date 01/27/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received01/27/2022
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date09/30/2022
Device Catalogue Number09211101190
Device Lot Number11028T
Is the Reporter a Health Professional? Yes
Date Manufacturer Received01/10/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? Yes
Patient Sequence Number1
-
-